Tweets
Basic Sci Year in Review:
Dr. Anne Davidson discusses the potential pathologic link bet tryptophan, indole, I3S & IL-17 pathways.
I3S induces epidermal thickening in mice and correlated with dse activity in patients with #psoriasis
#ACR25 @RheumNow https://t.co/WNNbBBESQ3
sheila @RHEUMarampa ( View Tweet )
5 months 2 weeks ago
Rheum guidelines balance data & context.
Beyond evidence, factors like cost, equity & feasibility shape recs.
GRADE-ADOLOPMENT = global tool to adopt, adapt, or design local guidance for more rapid integration and with less $$$
@RheumNow #ACR25 #GlobalRheumSummitt https://t.co/Sfsqxsqpt4
Jiha Lee @JihaRheum ( View Tweet )
5 months 2 weeks ago
RheumNow’s expanded coverage of the #ACR25 Annual Meeting is sponsored by Bristol Myers Squibb, Novartis, and UCB. All coverage content is independently selected by RheumNow and its faculty.
Dr. John Cush @RheumNow ( View Tweet )
5 months 2 weeks ago
12 yr study of 115 Systemic Sclerosis pts shows Finger-to-palm distance (tip 4th finger to distal palmar crease) may be a useful tool for predicting the progression of skin thickening and the development of digital ulcers in the early stages of severe SSc https://t.co/brCEz5Fqac https://t.co/kZMQ0UsimB
Dr. John Cush @RheumNow ( View Tweet )
5 months 2 weeks ago
From Eye on Cytokine Storm- Decoding MAS by Dr Grant Schulert : “IL-18 is highly elevated in SJIa and other autoinflammatory disorders…can amplify innate signaling as well as induce IFN-gamma”. @RheumNow #ACR2025 https://t.co/6e5yfeDepX
Gabriela Martinez Zayas, MD @MartinezZayasMd ( View Tweet )
5 months 2 weeks ago
🔥 Hot off the press
Prof John Stone shares results from Phase 3 of REPLENISH, out only a few days ago, in which secukinumab met all primary endpoints in treatment of PMR.
https://t.co/RlcQWybKrR
#ACR25 @RheumNow https://t.co/ucNt2HxJpW
Links:
Mrinalini Dey @DrMiniDey ( View Tweet )
5 months 2 weeks ago
Summary of updates in Vasculitis by Dr John Stone: 1. Anti-CD19 in IgG4Rd, 2. IL6 6R blockade in GCA/IL17i in PMR, 3. IL5RA+ ritux in EGPA. CART in AAV? @RheumNow #ACR2025 https://t.co/HxPNRE98Vl
Gabriela Martinez Zayas, MD @MartinezZayasMd ( View Tweet )
5 months 2 weeks ago
Telitacicept Effective in Systemic Lupus Erythematosus
The NEJM has published a report from van Vollenhoven et al showing a new dual B cell inhibitor, telitacicept, to be effective when given to active systemic lupus erythematosus (SLE) patients; but this comes with a few https://t.co/L0TgynLELD
Dr. John Cush @RheumNow ( View Tweet )
5 months 2 weeks ago
FDA has approved Genentech’s CD20-targeting antibody obinutuzumab (Gazyva) for the treatment of adult patients with lupus nephritis who are receiving standard therapy. https://t.co/0eGwGnSDYf https://t.co/wnQDVnTEjb
Dr. John Cush @RheumNow ( View Tweet )
5 months 2 weeks ago
Great to be with team @RheumNow reporting on the latest from #ACR25 https://t.co/h941qYSc6U
Antoni Chan MD (Prof) @synovialjoints ( View Tweet )
5 months 2 weeks ago
Casal Moura, M., Merkel, P.A., Jayne, D. et al.Challenges in the diagnosis, classification and prognosis of ANCA-associated vasculitis. Nat Rev Rheumatol (2025). https://t.co/fGUr2DnfwA
Good figure, citation above. Via
@AKronbichler and colleagues https://t.co/FGfPFiGgMv
Links:
Suleman Bhana, MD @DrBhana ( View Tweet )
5 months 2 weeks ago
Clinical and Genetic Effects of Neuropsychiatric Lupus
The clinical features and genetic abnormalities of neuropsychiatric systemic lupus erythematosus shows that NPSLE often means more severe lupus and more organ involvement beyond the central nervous system. https://t.co/7Ujo6Kaf1N
Dr. John Cush @RheumNow ( View Tweet )
5 months 2 weeks ago
